Cencora, Inc.

COR

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
COR
CIK0001140859
SIC5122
SectorWholesale Trade
Industry CategoryWholesale
Industry GroupWholesale – Drugs & Drug Proprietaries

Contact

Address1 WEST FIRST AVENUE, CONSHOHOCKEN, PA, 19428
Website www.cencora.com
Phone610-727-7000
CEOSteven H. Collis
Employees42,000

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$328.68 billion
Pre-Tax Income$3.51 billion
Net Income$2.55 billion
Net Income to Common$2.55 billion
EPS$13.05
View All
Balance Sheet
Cash$2.18 billion
Assets$81.65 billion
Liabilities$78.07 billion
Common Equity$3.40 billion
Liabilities & Equity$81.65 billion
View All
Cash Flow Statement
Calculations
NOPAT$2.03 billion
EBITDA$4.93 billion
Price to Earnings$21.47
Price to Book$16.10
ROE107.13%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.

Article Link

Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII

A new, smaller 60 mL bottle brings pharmacy-stocking and dosing convenience to a once-daily liquid amphetamine designed for individualized titration in ADHDMONMOUTH JUNCTION, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced the availability of DYANAVEL® XR (amphetamine) extended-release oral suspension, CII (2.5 mg/mL) in a new, smaller 60 mL bottle (NDC 24478-102-02)

Article Link

Is Cencora Stock Underperforming the Nasdaq?

Cencora has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

Article Link

Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?

Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Article Link

Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know

The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Article Link